Dossier assessment
Ivacaftor (combination with tezacaftor/ivacaftor, cystic fibrosis, 12 years and older, with F508del mutation, heterozygous) - Addendum to Commission A19-71
Report documents
-
Addendum
Ivacaftor (combination with tezacaftor/ivacaftor, cystic fibrosis, 12 years and older, with F508del mutation, heterozygous) - Addendum to Commission A19-71
Dossier assessment
Indication:
Cystic fibrosis in patients aged 12 years and older who are heterozygous for the F508del mutation in the CFTR gene
Result of dossier assessment:
Conclusion of dossier assessment A19-71 unchanged
Additional information
Federal Joint Committee (G-BA)
2020-02-20 A G-BA decision was published.
Project details
- Project no.
- A20-06
- Commission
- Commission awarded on 07.01.2020 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Airways and respiratory system
- Note
-
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
Connected Projects
-
Dossier assessment
Ivacaftor (combination with ivacaftor/tezacaftor, cystic fibrosis, 12 years and older, with F508del mutation, heterozygous) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed